Fernández-Miranda, J.J.; DÃaz-Fernández, S.; Cepeda-Piorno, F.J.; López-Muñoz, F.
Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes. Biomedicines 2024, 12, 165.
https://doi.org/10.3390/biomedicines12010165
AMA Style
Fernández-Miranda JJ, DÃaz-Fernández S, Cepeda-Piorno FJ, López-Muñoz F.
Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes. Biomedicines. 2024; 12(1):165.
https://doi.org/10.3390/biomedicines12010165
Chicago/Turabian Style
Fernández-Miranda, Juan José, Silvia DÃaz-Fernández, Francisco Javier Cepeda-Piorno, and Francisco López-Muñoz.
2024. "Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes" Biomedicines 12, no. 1: 165.
https://doi.org/10.3390/biomedicines12010165
APA Style
Fernández-Miranda, J. J., DÃaz-Fernández, S., Cepeda-Piorno, F. J., & López-Muñoz, F.
(2024). Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes. Biomedicines, 12(1), 165.
https://doi.org/10.3390/biomedicines12010165